Precigen (NASDAQ:PGEN) Upgraded to Hold at Wall Street Zen

Precigen (NASDAQ:PGEN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other analysts have also recently weighed in on PGEN. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Citizens Jmp upped their target price on shares of Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday. HC Wainwright lifted their price target on Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.50.

Precigen Trading Down 5.7%

NASDAQ:PGEN opened at $3.67 on Friday. The firm has a market capitalization of $1.30 billion, a P/E ratio of -2.74 and a beta of 1.10. The business has a 50 day simple moving average of $4.08 and a 200 day simple moving average of $3.98. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 3.95. Precigen has a 12-month low of $1.11 and a 12-month high of $5.47.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.09. The firm had revenue of $4.57 million for the quarter, compared to analyst estimates of $8.29 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%. Equities research analysts predict that Precigen will post -0.32 EPS for the current year.

Hedge Funds Weigh In On Precigen

Several large investors have recently bought and sold shares of PGEN. NBC Securities Inc. bought a new stake in shares of Precigen during the 4th quarter worth about $38,000. Mason Investment Advisory Services Inc. acquired a new stake in shares of Precigen in the 4th quarter worth approximately $42,000. Abel Hall LLC bought a new position in shares of Precigen in the fourth quarter valued at approximately $44,000. NewEdge Advisors LLC bought a new position in shares of Precigen in the fourth quarter valued at approximately $45,000. Finally, Asempa Wealth Advisors acquired a new position in shares of Precigen during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.